iShares Biotechnology ETF
520 hedge funds and large institutions have $5.06B invested in iShares Biotechnology ETF in 2017 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 179 increasing their positions, 186 reducing their positions, and 76 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
4% less repeat investments, than reductions
Existing positions increased: 179 | Existing positions reduced: 186
5% less funds holding in top 10
Funds holding in top 10: 21 → 20 (-1)
35% less call options, than puts
Call options by funds: $496M | Put options by funds: $763M
Holders
520
Holding in Top 10
20
Calls
$496M
Puts
$763M
Top Buyers
| 1 | +$191M | |
| 2 | +$160M | |
| 3 | +$73M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$72M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$69.2M |
Top Sellers
| 1 | -$39.9M | |
| 2 | -$35.6M | |
| 3 | -$31.5M | |
| 4 |
Jane Street
New York
|
-$30.6M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$30.1M |